Product
AI AGENTS
INTELLIGENCE SUITE
API, MCP & INTEGRATION
Solutions
INDUSTRIES
USE CASES
Pricing
Resources
EXPLORE
ENGAGE
SUPPORT & SERVICES
About
Patsnap Eureka Platform
IP Search Agents
IP Drafting Agents
Engineering Agents
Find Solutions with TRIZ
Life Sciences Agents
Materials Agents
SEP Agents
Patsnap Eureka Desktop
BetaAnalytics
IP IntelligenceSynapse
Biopharma IntelligenceBio
Biosequence Search and AnalysisChemical
Chemical Structure Search and AnalysisProfessional Services
Open Platform
Developer Center
Customer Stories
Newsroom
Blog
Global Innovation Report
Glossary
Free tools
NEWWebinars & Training
User Community
R&D Benchmark Calculator
Trust and Security
PatentBench
NEWLLM
Help center
Careers
Access to over 2,000,000,000 structured data points around patents, science, litigation, and tech sectors
Innovate 75% faster at 25% less cost
Cloud or on-prem for maximum privacy and control
Trusted by more than 18,000 innovators worldwide
To use , click the vertification button in the email we sent to [email protected].
This helps keep your account secure.
You should receive it shortly. Don’t forget to check your spam folder.
Already have an account? Log In
To start using Patsnap Eureka, click the verification button in the email we sent to .
This helps keep your account secure.
Haven't received it? Check your spam folder.
Thoughtfully curated series offering valuable insights for innovation professionals
Article | Report Key engineering considerations for high-reliability slip ring assemblies in wind turbine pitch control — materials, contact design, EMC, and standards guidance.
Article | Report Explore the 2026 EMI shielding materials landscape for 5G devices: key IPC codes, material categories, leading assignees, and how to run a full patent analysis.
Article | Report PIM vs active IMD in high-power RF antenna systems: key technical distinctions, design implications, and why patent data is essential for informed R&D decisions.
Article | Report Patent and research analysis of warehouse automation pick and place technology 2026: AMR fleets, RMFS, AI grasping, and human-robot collaboration trends.
Article | Report Spesolimab (Spevigo) blocks IL-36R to treat GPP and expanding IL-36 diseases. Explore Boehringer Ingelheim's Phase III pipeline and what it means for dermatology R&D.
Article | Report What stops CO₂ electroreduction from reaching industrial scale? Explore the key technical and economic barriers blocking cost-effective CO₂RR deployment.
Article | Report How do single-point and distributed fiber optic sensing systems differ for structural health monitoring? A technical guide to FBG, Brillouin, and Rayleigh sensing for civil infrastructure.
Article | Report How AnaptysBio's rosnilimab targets PD-1-high pathogenic T cells in rheumatoid arthritis — a mechanistically distinct immune tolerizing approach entering Phase III.
Article | Report Explore the low-k dielectric materials landscape for 3D IC packaging in 2026: key material classes, IPC codes, assignees, and how to navigate the IP space.
Article | Report Nuclear microreactors below 20 MWe are moving from prototype to factory production. Explore the 2026 technology landscape: KRUSTY, Holos-Quad, HALEU fuel, and manufacturing economics.
Article | Report A 2026 technology landscape of intestinal organoid disease modeling: key platforms, innovation clusters, application domains, and emerging R&D directions from 80+ records.
Article | Report Tarlatamab (Imdelltra) is expanding into limited-stage SCLC and first-line settings. Explore what the DLL3×CD3 BiTE data signals mean for SCLC drug development.
Article | Report Explore the key engineering challenges of next-generation electrochromic smart window systems—from ionic transport to large-area coating uniformity—for energy-efficient buildings.
Article | Report Explore the 2026 fuel cell bipolar plate materials landscape: graphite composites, metallic plates, coatings, and IP strategy insights from PatSnap Eureka.
Article | Report Talquetamab's GPRC5D mechanism, Phase III combination strategies, and competitive positioning against BCMA-targeted bispecific antibodies in relapsed/refractory myeloma.